Prices for prescription pharmaceuticals were nearly 3% higher during the third quarter of 1997 than during the third quarter of 1996, according to IMS America's Quarterly Pricing Report.
Prices for prescription pharmaceuticals were nearly 3% higher during the third quarter of 1997 than during the third quarter of 1996, according to IMS America's Quarterly Pricing Report.
IMS America, Plymouth Meeting, PA, attributed the 2.9% increase to a significantly slower decline in the prices of generics and increases in prices of branded products.
Overall prices for generics dropped at a rate of 6.4% compared with a year ago, while prices of branded prescription medicines rose 3.8%.
According to Myron Holubiak, general manager of IMS America's consulting arm, The Plymouth Group, total prescription sale growth in retail pharmacies, hospitals, clinics, staff-model HMOs, long-term care facilities and federal facilities was 17.3% higher than it was a year ago.
"Non-price factors, such as increased volume and mix of products, combined with exceptional growth in new products appeared to be dominant industry drivers," Holubiak said. "Several significant new products introduced late last year have already broken into the top 100 best-selling drugs."
He added that third-party coverage for prescription products increased, and increased coverage is associated with increased demand for prescription products. Medicare beneficiaries, who are rapidly joining managed care plans, play a major role in this growth. According to IMS America, Medicare beneficiaries increase drug expenditures nearly twofold when they have greater access to a prescription drug plan. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.